Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma (OS). She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Her phase II clinical trials done at MD Anderson demonstrated that liposomal MTP-PE therapy activated the tumoricidal properties of macrophages, prolonged disease-free survival and could be combined with chemotherapy. The success of these trials led to a national phase III trial sponsored by the Children’s Oncology Group. Newly diagnosed osteosarcoma patients treated with liposomal MTP-PE plus chemotherapy has a 30% reduction in mortality rate compared to the patients that received chemotherapy alone. This demonstration of efficacy led to the approval of liposomal MTP-PE by the European Medicine Agency, which is now part of the Standard of care in the U.L., Italy, Israel and Turkey. MTP-PE is available in 27 countries in the European Union. Dr. Kleinerman’s pioneering use of this immunotherapeutic agent in children with osteosarcoma resulted in the first improvement in long term survival of children with this disease in over 25 years.